





## **AUDITORS' REPORT**

on

# **Utilization of IPO Proceeds**

We have audited the annexed Statement of Initial Public Offering (IPO) Proceeds Utilization of Silva Pharmaceuticals Limited for the month ended 30 April 2021 as per required by Bangladesh Securities and Exchange and Commission (BSEC) under Section 2CC of the Securities and Exchange Ordinance 1969.

# Management's Responsibility for the IPO proceeds Utilization

Management is responsible for the preparation and fair presentation of these IPO proceeds utilization statement in accordance with Bangladesh Securities and Exchange Commission Rules 1987, Condition laid down in clause 2, 3, 5 & 6 of PART- C of consent letter # BSEC/CI/IPO-269/2017/429, Dated June 28, 2018 and other applicable laws and regulations.

## Auditor's Responsibility

Our responsibility is to express an independent opinion on these Initial Public Offering (IPO) proceeds utilization statement based on our audit. We conducted our audit in accordance with International Standards on Auditing (ISA), Bangladesh Securities and Exchange Commission Rules 1987, Condition laid down in clause 2, 3, 5 & 6 of PART- C of consent letter # BSEC/CI/IPO-269/2017/429, Dated June 28, 2018 and other applicable laws and regulations.

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion.

# Opinion

In our Opinion, the Statement of Initial Public Offering (IPO) Proceeds Utilization, prepared in accordance with Bangladesh Securities and Exchange Commission Rules 1987 and Condition laid down in clause 2, 3, 5 of PART- C of consent letter # BSEC/CI/IPO-269/2017/429, Dated June 28, 2018 and other applicable laws and regulations, gives a true and fair view of the statement for the month 30 April 2021.

# As per TOR, we draw attention to the following matter:

 During the month of April , 2021 no expenses has been incurred in respect of Civil Construction. However, the company has utilized accumulative amount of Tk. 60,532,650 up to 30 April 2021 which was 104.26% of the amount specified in the prospectus and thereafter revised utilization plan for the purpose of Civil Construction. As such, approval was a pre-requisite from the respected shareholders and concerned regulatory authority for the excess utilized amount of Tk. 2,474,124.







- During the month of April, 2021 no expenses has been incurred in respect of Purchase new Machinery and Equipment's. However, the company has utilized accumulative amount of Tk. 29,569,142 which was 24.14% up to 30 April 2021 in respect of Purchase of Machinery and Equipment's.
- 3. The Company has utilized Tk. 99,000,000 which was 100% of the budgeted amount up to 30 April 2021 for the purpose of loan repayment as specified in the prospectus.
- 4. The Company has utilized Tk. 20,441,474 which was 100% of the budgeted amount up to 30 April 2021 for the purpose of IPO expenses as specified in the prospectus and thereafter revised utilization plan.

### We also state that:

- a) IPO proceeds have been utilized for the purposes as specified in the prospectus and thereafter revised utilization plan except the above said issues no.1 of the Company;
- b) IPO proceeds have been utilized in so far line with the conditions of the BSEC's consent letter for the IPO except the above said issues no. 1.
- c) The time frame for completion of the utilization of IPO proceeds was revised and will be completed within the time frame as specified in the resolution of 19<sup>th</sup> Annual General Meeting (AGM).
- d) Utilization of IPO proceeds is accurate for the purpose of the company as mentioned in the prospectus and 18<sup>th</sup> AGM of the Company.
- e) Audit statement has been made on verification of all necessary documents/papers/vouchers in support of utilization of IPO proceeds making reconciliation with bank statements.

Dhaka

Dated: 06 May, 2021

Mohan Adhikari, FCA Partner

(ICAB Enroll no: 1729) **Pinaki & Company**Chartered Accountants





(Amount in BDT)

# Report on Utilization of IPO Proceeds For the Month of April 2021

: Silva Pharmaceuticals Limited

BDT 300,000,000 05 August 2018

10 October 2018

Last Date of Full Utilization of IPO Fund as per Prospectus

S.L

Amount (BDT) of capital raised through IPO:

Name of the Company:

Date of Close of Subscription:

Proceeds Receiving Date

As stated in time line columns

		Timo Lino						57	Status of Utilization	lization				
Purpose mentioned in the prospectus / 18th AGM	As per Prospectus	4	_	Amount as Amount as per Prospectus per 18th AGM	Amount as per 18th AGM	Opening	During the Month	During the Total Utilized U	Utilized %	Excess Utilized amount	Excess- utilized %	Total unutilized amount	Un -utilized Remarks	Remarks
Civil Construction	09.04.2020	09.04.2020 09.10.2020	31.12.2022	26,000,000	58,058,526	60,532,650	,	60,532,650	104.26	2,474,124	4.26		•	
Machinery and Equipment 09 04, 2020 09, 10, 2020	09.04.2020	09.10.2020	31.12.2022	122,500,000	122,500,000	29,569,142		29,569,142	24.14	1		92,930,858	75.86	
Repayment of Bank Borrowing at prospectus	09.01.2019	N/A	N/A	000,000,66	000'000'66	000,000,66		000,000,66	100.00	1			-	
IPO Expenses	N/A	N/A	N/A	22,500,000	20,441,474	20,441,474		20,441,474	100.00	1		•	-	
	Total			300,000,000	300,000,000	209,543,265		209,543,265		69.85 2,474,124	0.82	92,930,858	30.98	

20,916,083 111,372,818

b) IPO proceeds have been utilized for the purposes/heads as seecified in the propectus and in line with the condition of the Commission's consent letter.

a) Actual application was received almost 25.76 Times.

d) Un-Utilized IPO Proceeds with interest income in BDT c) Interest on IPO Proceeds in BDT (from FDR & SND) -

Chief Financial Officer Md. Abul Kasem

Managing Director Dr. Saira Khan

Alinza. Silvana Mirza Dhaka Dated: 06 May 2021